Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer

BACKGROUND: Only a fraction of patients with advanced non-small cell lung cancer (NSCLC) respond well to immune checkpoint blockade (ICB) therapy. Here, we investigated whether Titin (TTN) mutation, which has been demonstrated to be a predictive biomarker in tissue-based analysis, can identify patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Chunxia, Wang, Xinxin, Zhou, Juan, Zhao, Jing, Zhou, Fei, Zhao, Guodong, Xu, Xiaohong, Zou, Xuan, Zhu, Bo, Jia, Qingzhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044474/
https://www.ncbi.nlm.nih.gov/pubmed/33889507
http://dx.doi.org/10.21037/tlcr-20-1118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044474/
https://www.ncbi.nlm.nih.gov/pubmed/33889507
http://dx.doi.org/10.21037/tlcr-20-1118

Ejemplares similares